Scaled-up manufacturing of recombinant antibodies produced by plant cells in a 200-L orbitally-shaken disposable bioreactor

Biotechnology and Bioengineering

Volumn 112, Issue 2, 2015, Pages 308-321

  Raven, Nicole ^a   Rasche, Stefan ^a   Kuehn, Christoph ^a   Anderlei, Tibor ^b   Klöckner, Wolf ^c   Schuster, Flora ^d   Henquet, Maurice ^e   Bosch, Dirk ^e,f   Büchs, Jochen ^d   Fischer, Rainer ^a,d   Schillberg, Stefan ^a,g  

^a FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

^b ADOLF KÜHNER AG   (Switzerland)

^c BAYER AG   (Germany)

^d RWTH AACHEN UNIVERSITY   (Germany)

^e WAGENINGEN UNIVERSITY   (Netherlands)

^f UTRECHT UNIVERSITY   (Netherlands)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Antibody purification; Expanded bed chromatography; Nicotiana tabacum bright yellow 2 (BY 2); Plant cell suspension culture; Scaled up manufacture; Single use technology

Indexed keywords

AFFINITY CHROMATOGRAPHY; BIOCONVERSION; BIOREACTORS; CELL CULTURE; CELLS; CHROMATOGRAPHY; CLARIFICATION; CYTOLOGY; MANUFACTURE; MONOCLONAL ANTIBODIES; PLANT CELL CULTURE; PROTEINS; PURIFICATION; RECOMBINANT PROTEINS; STAINLESS STEEL;

ANTIBODY PURIFICATION; EXPANDED BEDS; NICOTIANA TABACUM; PLANT CELL SUSPENSION CULTURES; SCALED-UP; SINGLE USE;

ANTIBODIES;

HUMAN MONOCLONAL ANTIBODY M12; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; VITRONECTIN; MONOCLONAL ANTIBODY; POLYSACCHARIDE; RECOMBINANT PROTEIN;

ANTIBODY PRODUCTION; ARTICLE; BIOREACTOR; BY 2 CELL; CELL GROWTH; DOWNSTREAM PROCESSING; EXPANDED BED CHROMATOGRAPHY; OXYGEN CONSUMPTION; PLANT CELL; PROTEIN PURIFICATION; SCALE UP; STIRRED REACTOR; SUSPENSION CELL CULTURE; CELL LINE; GENETICS; HUMAN; METABOLISM; TOBACCO; TRANSGENIC PLANT;

ANTIBODIES, MONOCLONAL; BIOREACTORS; CELL LINE; HUMANS; PLANT CELLS; PLANTS, GENETICALLY MODIFIED; POLYSACCHARIDES; RECOMBINANT PROTEINS; TOBACCO;

EID: 84920191560     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.25352     Document Type: Article

References (84)

1. An G. 1985. High efficiency transformation of cultured tobacco. Plant Physiol 79(2):568-570.
2. Anspach FB, Curbelo D, Hartmann R, Garke G, Deckwer WD. 1999. Expanded-bed chromatography in primary protein purification. J Chromatogr A 865(1-2):129-144.
3. Batt BC, Yabannavar VM, Singh V. 1995. Expanded bed adsorption process for protein recovery from whole mammalian cell culture broth. Bioseparation 5(1):41-52.
4. Beck JT, Williamson B, Tipton B. 1999. Direct coupling of expanded bed adsorption with a downstream purification step. Bioseparation 8(1-5):201-207.
5. Bendandi M, Marillonnet S, Kandzia R, Thieme F, Nickstadt A, Herz S, Fröde R, Inogés S, Lòpez-Dìaz de Cerio A, Soria E, Villanueva H, Vancanneyt G, McCormick A, Tusé D, Lenz J, Butler-Ransohoff JE, Klimyuk V, Gleba Y. 2010. Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann Oncol 21(12):2420-2427.
6. Bevan MW, Flavell RB, Chilton MD. 1983. A chimaeric antibiotic resistance gene as a selectable marker for plant cell transformation. Nature 304:184-187.
7. Blank GS, Zapata G, Fahrner R, Milton M, Yedinak C, Knudsen H, Schmelzer C. 2001. Expanded bed adsorption in the purification of monoclonal antibodies: A comparison of process alternatives. Bioseparation 10(1-3):65-71.
8. Bloemendal HJ, de Boer HC, Koop EA, van Dongen AJ, Goldschmeding R, Landman WJM, Logtenberg T, Gebbink MFBG, Voest EE. 2004. Activated vitronectin as a target for anticancer therapy with human antibodies. Cancer Immunol Immunother 53(9):799-808.
9. Bosch D, Castilho A, Loos A, Schots A, Steinkellner H. 2013. N-glycosylation of plant-produced recombinant proteins. Curr Pharm Des 19(31):5503-5512.
10. Christou P. 2013. From medicinal plants to medicines in plants: Plant factories for the production of valuable pharmaceuticals. Curr Pharm Des 19(31):5469-5470.
11. Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, Black A, Passmore D, Moldovan-Loomis C, Srinivasan M, Cuison S, Cardarelli PM, Dickey LF. 2006. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 24(12):1591-1597.
12. Doran PM. 2013. Therapeutically important proteins from in vitro plant tissue culture systems. Curr Med Chem 20(8):1047-1055.
13. Durocher Y, Butler M. 2009. Expression systems for therapeutic glycoprotein production. Curr Opin Biotechnol 20(6):700-707.
14. Eibl R, Eibl D. 2006. Design and use of the wave bioreactor for plant cell culture. In: Gupta SD, Ibaraki Y, editors Plant tissue culture engineering. Dordrecht, Netherlands: Springer. p 203-227.
15. Eibl R, Eibl D. 2009. Design of bioreactors suitable for plant cell and tissue cultures. Phytochem Rev 7(3):593-598.
16. Eibl R, Kaiser S, Lombriser R, Eibl D. 2010. Disposable bioreactors: the current state-of-the-art and recommended applications in biotechnology. Appl Microbiol Biotechnol 86(1):41-49.
17. Fairbanks G, Steck TL, Wallach DF. 1971. Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane. Biochemistry 10:2606-2617.
18. Farid SS. 2007. Process economics of industrial monoclonal antibody manufacture. J Chromatogr B 848(1):8-18.
19. Farid SS, Washbrook J, Titchener-Hooker NJ. 2005. Decision-support tool for assessing biomanufacturing strategies under uncertainty: Stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol Prog 21(2):486-497.
20. Fischer R, Schillberg S, Buyel JF, Twyman RM. 2013. Commercial aspects of pharmaceutical protein production in plants. Curr Pharm Des 19(31):5471-5477.
21. Fischer R, Schillberg S, Hellwig S, Twyman RM, Drossard J. 2012. GMP issues for recombinant plant-derived pharmaceutical proteins. Biotechnol Adv 30(2):434-439.
22. Fuller M. 2008. Introducing disposable systems into biomanufacturing. BioProcess Int 6(10):30-36.
23. Go EP, Rebecchi KR, Dalpathado DS, Bandu ML, Zhang Y, Desaire H. 2007. GlycoPep DB: A tool for glycopeptide analysis using a "Smart Search". Anal Chem 79(4):1708-1713.
24. Häkkinen ST, Raven N, Henquet M, Laukkanen M-L, Anderlei T, Pitkänen J-P, Twyman RM, Bosch D, Oksman-Caldentey K-M, Schillberg S, Ritala A. 2014. Molecular farming in tobacco hairy roots by triggering the secretion of a pharmaceutical antibody. Biotechnol Bioeng 111(2):336-346.
25. Havenith H, Raven N, Di Fiore S, Fischer R, Schillberg S. 2014. Image-based analysis of cell-specific productivity for plant cell suspension cultures. Plant Cell Tiss Organ Cult 86(1):41-49.
26. Hellwig S, Drossard J, Twyman RM, Fischer R. 2004. Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 22(11):1415-1422.
27. Hofbauer A, Stoger E. 2013. Subcellular accumulation and modification of pharmaceutical proteins in different plant tissues. Curr Pharm Des 19(31):5495-5502.
28. Holland T, Blessing D, Hellwig S, Sack M. 2013. The in-line measurement of plant cell biomass using radio frequency impedance spectroscopy as a component of process analytical technology. Biotechnol J 8(10):1231-1240.
29. Holland T, Sack M, Rademacher T, Schmale K, Altmann F, Stadlmann J, Fischer R, Hellwig S. 2010. Optimal nitrogen supply as a key to increased and sustained production of a monoclonal full-size antibody in BY-2 suspension culture. Biotech Bioeng 107(2):278-289.
30. Hossler P, Khattak SF, Li ZJ. 2009. Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19(9):936-949.
31. Huang LF, Liu YK, Lu CA, Hsieh SL, Yu SM. 2005. Production of human serum albumin by sugar starvation induced promoter and rice cell culture. Transgenic Res 14(5):569-581.
32. Huang S. 2009. Non-genetic heterogeneity of cells in development: More than just noise. Development 136(23):3853-3862.
33. Huang T-K, McDonald KA. 2012. Bioreactor systems for in vitro production of foreign proteins using plant cell cultures. Biotechnol Adv 30(2):398-409.
34. Jach G, Binot E, Frings S, Luxa K, Schell J. 2001. Use of red fluorescent protein from Discosoma sp. (dsRED) as a reporter for plant gene expression. Plant J 28(4):486-491.
35. Johansson HJ, Jägersten C, Shiloach J. 1996. Large scale recovery and purification of periplasmic recombinant protein from E. coli using expanded bed adsorption chromatography followed by new ion exchange media. J Biotechnol 48(1-2):9-14.
36. Kay R, Chan A, Daly M, McPherson J. 1987. Duplication of CaMV 35S promoter sequence creates a strong enhancer for plant genes. Science 236(4806):1299-1302.
37. Kelley B. 2007. Very large scale monoclonal antibody purification: The case for conventional unit operations. Biotechnol Prog 23(5):995-1008.
38. Kelley B. 2009. Industrialization of mAb production technology: The bioprocessing industry at a crossroads. MAbs 1(5):443-452.
39. Kim JY, Kim YG, Lee GM. 2012. CHO cells in biotechnology for production of recombinant proteins: Current state and further potential. Appl Microbiol Biotechnol 93(3):917-930.
40. Kirchhoff J, Raven N, Boes A, Roberts JL, Russell S, Treffenfeldt W, Fischer R, Schinkel H, Schiermeyer A, Schillberg S. 2012. Monoclonal tobacco cell lines with enhanced recombinant protein yields can be generated from heterogeneous cell suspension cultures by flow sorting. Plant Biotechnol J 10(8):936-944.
41. Klöckner W, Büchs J. 2012. Advances in shaking technologies. Trends Biotechnol 30(6):307-314.
42. La and relevant operating parameters in cylindrical disposable shaken bioreactors on a bench-to-pilot scale. J Biol Eng 28:1-14.
43. Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, Vézina LP. 2010. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5(12):e15559. doi: 10.1371/journal.pone.0015559
44. Lee YS, Suh CW, Park SK, Lee EG. 2003. Purification of soluble human epidermal growth factor (hEGF) from recombinant Escherichia coli culture broth by using expanded-bed adsorption chromatography. Biotechnol Appl Biochem 38(1):9-13.
45. Liu CM, Hong LN. 2001. Development of a shaking bioreactor system for animal cell cultures. Biochem Eng J 7(2):121-125.
46. Menkhaus TJ, Glatz CE. 2005. Antibody capture from corn endosperm extracts by packed bed and expanded bed adsorption. Biotechnol Prog 21(2):473-485.
47. Mison D, Curling J. 2000. The industrial production costs of recombinant therapeutic proteins expressed in transgenic corn. BioPharm 13(24):48-54.
48. Muller N, Girard P, Hacker DL, Jordan M, Wurm FM. 2005. Orbital shaker technology for the cultivation of mammalian cells in suspension. Biotechnol Bioeng 89(4):400-406.
49. Nagata T, Nemoto Y. 1992. Tobacco BY-2 cell line as the "HeLa" cell in the cell biology of higher plants. Int Rev Cytol 132:1-30.
50. Nandi S, Yalda D, Lu S, Nikolov Z, Misaki R, Fujiyama K, Huang N. 2005. Process development and economic evaluation of recombinant human lactoferrin expressed in rice grain. Transgenic Res 14(3):237-249.
51. Novais JL, Titchener-Hooker NJ, Hoare M. 2001. Economic comparison between conventional and disposable-based technology for the production of biopharmaceuticals. Biotechnol Bioeng 75(2):143-153.
52. Ohashi R, Otero JM, Chwistek A, Yamato I, Hamel JFP. 2002. On-line purification of monoclonal antibodies using an integrated stirred-tank reactor/expanded-bed adsorption system. Biotechnol Prog 18(6):1292-1300.
53. Pandey A, Singh N, Sambhara S, Mittal SK. 2010. Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses. Hum Vaccine 6(2):178-188.
54. Pelham HR. 1990. The retention signal for soluble proteins of the endoplasmic reticulum. Trends Biochem Sci 15(12):483-486.
55. Peuscher A, Gassler N, Schneider U, Thom P, Rasche S, Spiegel H, Schillberg S. 2014. An immunohistochemical assay on human tissue using a human primary antibody. J Immunoassay Immunochem 35(3):322-334.
56. Rademacher T, Sack M, Arcalis E, Stadlmann J, Balzer S, Altmann F, Quendler H, Stiegler G, Kunert R, Fischer R, Stoger E. 2008. Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol J 6(2):189-201.
57. Raven N, Schillberg S, Kirchhoff J, Braendli J, Imseng N, Eibl R. 2010. Growth of BY-2 suspension cells and plantibody production in single-use bioreactors. In: Eibl R, Eibl D, editors Single-use technology in biopharmaceutical manufacture, part II. Hoboken, New Jersey: John Wiley & Sons, Inc. p 251-261.
58. Reuter LJ, Bailey MJ, Joensuu JJ, Ritala A. 2014. Scale-up of hydrophobin-assisted recombinant protein production in tobacco BY-2 suspension cells. Plant Biotechnol J 12(4):402-410.
59. Rischer H, Häkkinen ST, Ritala A, Seppänen-Laakso T, Miralpeix B, Capell T, Christou P, Oksman-Caldentey KM. 2013. Plant cells as pharmaceutical factories. Curr Pharm Des 19(31):5640-5660.
60. Rival S, Wisniewski J-P, Langlais A, Kaplan H, Freyssinet G, Vancanneyt G, Vunsh R, Perl A, Edelman M. 2008. Spirodela (duckweed) as an alternative production system for pharmaceuticals: A case study, aprotinin. Transgenic Res 17(4):503-513.
61. Rouf SA, Moo-Young M, Scharer JM, Douglas PL. 2000. Single versus multiple bioreactor scale-up: Economy for high-value products. Biochem Eng J 6(1):25-31.
62. Sack M, Paetz A, Kunert R, Bomble M, Hesse F, Stiegler G, Fischer R, Katinger H, Stoeger E, Rademacher T. 2007. Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures. FASEB J 21(8):1655-1664.
63. Schillberg S, Raven N, Fischer R, Twyman RM, Schiermeyer A. 2013. Molecular farming of pharmaceutical proteins using plant suspension tissue cultures. Curr Pharm Des 19(31):5531-5542.
64. Schmale K, Rademacher T, Fischer R, Hellwig S. 2006. Towards industrial usefulness-cryo-cell-banking of transgenic BY-2 cell cultures. J Biotechnol 124(1):302-311.
65. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH, Aviezer D. 2007. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Plant Biotechnol J 5(5):579-590.
66. Shoji Y, Chichester JA, Bi H, Musiychuk K, de la Rosa P, Goldschmidt L, Horsey A, Ugulava N, Palmer GA, Mett V, Yusibov V. 2008. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 26(23):2930-2934.
67. Shukla AA, Thoemmes J. 2010. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28(5):253-261.
68. Trexler MM, McDonald KA, Jackman AP. 2002. Bioreactor production of human alpha(1)-antitrypsin using metabolically regulated plant cell cultures. Biotechnol Prog 18(3):501-508.
69. Vaquero C, Sack M, Chandler J, Drossard J, Schuster F, Monecke M, Schillberg S, Fischer R. 1999. Transient expression of a tumor-specific single-chain fragment and a chimeric antibody in tobacco leaves. Proc Natl Acad Sci USA 96(20):11128-11133.
70. Vasilev N, Grömping U, Lipperts A, Raven N, Fischer R, Schillberg S. 2013. Optimization of BY-2 cell suspension culture medium for the production of a human antibody using a combination of fractional factorial designs and the response surface method. Plant Biotechnol J 11(7):867-874.
71. Voss A, Niersbach M, Hein R, Hirsch HJ, Liao YC, Kreuzaler F, Fischer R. 1995. Reduced virus infectivity in N. tabacum secreting a TMV-specific full-size antibody. Mol Breeding 1(1):39-50.
72. Walsh G. 2010. Biopharmaceutical benchmarks 2010. Nat Biotechnol 28(9):917-924.
73. Weathers PJ, Towler MJ, Xu J. 2010. Bench to batch: Advances in plant cell culture for producing useful products. Appl Microbiol Biotechnol 85(5):1339-1351.
74. Webster DE, Thomas MC. 2012. Post-translational modification of plant-made foreign proteins; glycosylation and beyond. Biotechnol Adv 30(2):410-418.
75. Weikert S, Papac D, Briggs J, Cowfer D, Tom S, Gawlitzek M, Lofgren J, Mehta S, Chisholm V, Modi N, Eppler S, Carroll K, Chamow S, Peers D, Berman P, Krummen L. 1999. Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechnol 17(11):1116-1121.
76. Werner RG. 2004. Economic aspects of commercial manufacture of biopharmaceuticals. J Biotechnol 113(1-3):171-182.
77. Wong C, Sridhara S, Bardwell JC, Jakob U. 2000. Heating greatly speeds Coomassie blue staining and destaining. BioTechniques 28(3):426-432.
78. Wurm FM, Johnson A, Ryll T, Köhne C, Scherthan H, Glaab F, Lie YS, Petropoulos CJ, Arathoon WR. 1996. Gene transfer and amplification in CHO cells. Efficient methods for maximizing specific productivity and assessment of genetic consequences. Ann N Y Acad Sci 15(782):70-78.
79. Xu J, Ge X, Dolan MC. 2011. Towards high-yield production of pharmaceutical proteins with plant cell suspension cultures. Biotechnol Adv 29(3):278-299.
80. Xu X, Hirpara J, Epting K, Jin M, Ghose S, Rieble S, Li ZJ. 2013. Clarification and capture of high-concentration refold pools for E. coli-based therapeutics using expanded bed adsorption chromatography. Biotechnol Prog 30(1):113-123.
81. Yusibov V, Streatfield SJ, Kushnir N. 2011. Clinical development of plant-produced recombinant pharmaceuticals: Vaccines, antibodies and beyond. Hum Vaccin 7(3):313-321.
82. Zhang X, Bürki C-A, Stettler M, De Sanctis D, Perrone M, Discacciati M, Parolini N, DeJesus M, Hacker DL, Quarteroni A, Wurm FM. 2009. Efficient oxygen transfer by surface aeration in shaken cylindrical containers for mammalian cell cultivation at volumetric scales up to 1, 000L. Biochem Eng J 45(1):41-47.
83. Zhang X, Stettler M, De Sanctis D, Perrone M, Parolini N, Discacciati M, De Jesus M, Hacker D, Quarteroni A, Wurm F. 2010. Use of orbital shaken disposable bioreactors for mammalian cell cultures from the milliliter-scale to the 1, 000-liter scale. Adv Biochem Eng Biotechnol 115:33-53.
84. Zimran A, Brill-Almon E, Chertkoff R, Petakov M, Blanco-Favela F, Munoz ET, Solorio-Meza SE, Amato D, Duran G, Giona F, Heitner R, Rosenbaum H, Giraldo P, Mehta A, Park G, Phillips M, Elstein D, Altarescu G, Szleifer M, Hashmueli S, Aviezer D. 2011. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 118(22):5767-5773.